Verona Pharma’s investigational agent RPL554 will be named ensifentrine, the company announced. The “-fentrine” stem in the International…
Articles by Alice Melão, MSc
Theravance Biopharma and Mylan announced that the U.S. Food and Drug Administration (FDA) approved their New Drug Application…
A fully functional 3D-printed artificial lung may someday help people with serious pulmonary illnesses, such as chronic obstructive pulmonary…
The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to…
AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate…
Psychological distress, even at low or moderate levels, increases the risk of arthritis, cardiovascular disease, and chronic obstructive pulmonary…
A new clinical trial being conducted in the United Kingdom is recruiting participants to study the early stages of…
Preliminary results from a Phase 2 trial show that Synairgen’s investigative therapy SNG001 is well-tolerated by patients with…
The investigational monoclonal antibody Fasenra (benralizumab) failed to reduce exacerbations in patients with moderate to very severe chronic obstructive…
AB569, Arch Biopartners’ lead therapy candidate, has received a U.S. patent for the treatment of chronic lung infections in patients…